Skip to main content
رجوع
TAK logo

Takeda Pharmaceutical Company Limited

جودة البيانات: 100%
TAK
NYSE Healthcare Drug Manufacturers - Specialty & Generic
KWD 18.04
▲ KWD 0.18 (1.01%)
القيمة السوقية: 56.99B
مُدرج أيضًا باسم TKPHF OTC
نطاق اليوم
KWD 17.79 KWD 18.11
نطاق 52 أسبوعًا
KWD 12.99 KWD 18.82
حجم التداول
3,081,516
متوسط 50 يوم / 200 يوم
KWD 17.61 / KWD 15.40
الإغلاق السابق
KWD 17.86

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 0.5 0.4
P/B 0.0 2.9
ROE % 1.5 3.7
Net Margin % 2.4 3.9
Rev Growth 5Y % 9.4 10.0
D/E 0.7 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 162.650
KWD 156.763 – KWD 166.232
 5000 B 1
FY2029 KWD 133.375
KWD 128.547 – KWD 136.312
 4900 B 1
FY2028 KWD 106.603
KWD 102.744 – KWD 108.950
 4700 B 1

Insider Trading Activity

8 transactions
Date Insider Type Shares Price Value
Feb 28, 2026
Lo Andrew Tak Shing
Senior Managing Director
 grant 227,637 — —
Feb 28, 2026
Lo Andrew Tak Shing
Senior Managing Director
 other 66,848 — —
Feb 2, 2026
Wu Ping Tak
VP, U.S. Operations
 grant 15,000 — —
Jan 26, 2026
Tak Paul Peter
Chief Executive Officer
 grant 629,000 — —
Aug 4, 2025
Wu Ping Tak
VP, U.S. Operations
 grant 30,000 — —
Jun 25, 2025
Tak Paul Peter
Chief Executive Officer
 grant 42,826 KWD 4.670 KWD 199,997
Jun 24, 2025
YU Wing Tak Wendy
Director
 grant 20,000 — —
May 5, 2025
Wu Ping Tak
VP, U.S. Operations
 grant 15,000 — —

النقاط الرئيسية

Revenue grew 9.41% annually over 5 years — modest growth
Earnings declined -25.08% over the past year
ROE of 1.52% is below average
Generating 856.39B in free cash flow
P/E of 0.53 — trading at a low valuation
Cash machine — converts 793.48% of earnings into free cash flow

النمو

Revenue Growth (5Y)
9.41%
Revenue (1Y)7.45%
Earnings (1Y)-25.08%
FCF Growth (3Y)57.90%

الجودة

Return on Equity
1.52%
ROIC2.24%
Net Margin2.36%
Op. Margin7.48%

الأمان

Debt / Equity
0.65
Current Ratio1.01
Interest Coverage2.50

التقييم

P/E Ratio
0.53
P/B Ratio0.01
EV/EBITDA12.22
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.45% Revenue Growth (3Y) 6.66%
Earnings Growth (1Y) -25.08% Earnings Growth (3Y) -41.65%
Revenue Growth (5Y) 9.41% Earnings Growth (5Y) -26.80%
Profitability
Revenue (TTM) 4.58T Net Income (TTM) 107.93B
ROE 1.52% ROA 0.76%
Gross Margin 65.51% Operating Margin 7.48%
Net Margin 2.36% Free Cash Flow (TTM) 856.39B
ROIC 2.24% FCF Growth (3Y) 57.90%
Safety
Debt / Equity 0.65 Current Ratio 1.01
Interest Coverage 2.50 Dividend Yield 0.04%
Valuation
P/E Ratio 0.53 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio -2.57
EV/EBITDA 12.22 Dividend Yield 0.04%
Market Cap 56.99B Enterprise Value 4.19T

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 4.58T 4.26T 4.03T 3.57T 3.20T
Net Income 107.93B 144.07B 317.02B 230.06B 376.01B
EPS (Diluted) 33.62 45.58 100.97 72.94 119.48
Gross Profit 3.00T 2.83T 2.78T 2.46T 2.20T
Operating Income 342.59B 214.08B 490.51B 460.84B 509.27B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 14.25T 15.11T 13.96T 13.18T 12.91T
Total Liabilities 7.31T 7.83T 7.60T 7.49T 7.74T
Shareholders' Equity 6.94T 7.27T 6.35T 5.68T 5.17T
Total Debt 4.52T 4.84T 4.38T 4.35T 4.64T
Cash & Equivalents 385.11B 457.80B 533.53B 849.70B 966.22B
Current Assets 2.52T 2.56T 2.40T 2.59T 2.71T
Current Liabilities 2.51T 2.31T 2.48T 2.15T 1.77T

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#44 of 1024
78

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026